Starting a company and taking it public has long been the goal of many biotechnology entrepreneurs and the venture capitalists that back them.
Now, though, with the stock market unreceptive and pharmaceutical companies desperate for new products, some small privately held biotech companies are choosing a more certain if potentially less spectacular payoff: selling themselves to larger companies.
The latest example came on Tuesday, when Peninsula Pharmaceuticals, a four-year-old developer of antibiotics, agreed to be acquired by Johnson & Johnson for US$245 million. Peninsula, based in California, had filed for an initial public stock offering (IPO) but postponed it while negotiating the acquisition.
The deal follows one last month by TransForm Pharmaceuticals, a privately held Massachusetts firm, that also agreed to be acquired by Johnson & Johnson for US$230 million.
Other recent deals involving takeovers of private companies include Xcel Pharmaceuticals by Valeant Pharmaceuticals, Syrrx by Takeda Pharmaceutical, Idun Pharmaceuticals by Pfizer, Angiosyn by Pfizer, and ESP Pharma by Protein Design Labs.
Pharmaceutical companies, of course, have long acquired biotechnology companies, both public and private ones. But the recent deals tend to be larger than before.
According to VentureOne, which tracks the venture capital industry, the seven acquisitions of private biopharmaceutical firms in the first quarter were worth US$2 billion. While the number of deals is not unusual, that value exceeds the US$1.2 billion for all 31 such deals done last year.
The shift reflects a confluence of forces. Only four US biotech companies have gone public this year, and they typically had to reduce their offering price to get the deal done.
And since venture investors do not always sell all their shares at the time of the IPO, they must consider what may happen to a company's stock after it goes public. Biotech stocks have been slumping lately, in part because of the withdrawal from the market for safety reasons of Tysabri, a biotech multiple-sclerosis drug marketed by Biogen Idec and Elan that was supposed to be a blockbuster.
Those factors have changed the dynamics.
Peninsula hoped to raise US$70 million to US$80 million in an offering that would have valued it at US$290 million to US$340 million.
The Johnson & Johnson deal for US$245 million appears to be worth less. But Johnson & Johnson is acquiring only one of two antibiotics Peninsula is developing. The other one will be spun off into a new company that will be largely owned by the current owners of Peninsula. With market conditions as they are, moreover, it is far from certain that the Peninsula stock offerings would have succeeded at the desired price.
"We chose the option that gave us the most certain liquidity," said Lowell Sears of Sears Capital Management, a venture backer and a director of Peninsula.
Right now, it appears that pharmaceutical companies are placing a higher value on these small companies than public markets might. But that still is not as high a value as they might receive through a public offering during good times.
"We made a nice profit on this investment, but we didn't make 10 times our money, and for the good public ones, we tend to do that," said James Blair of Domain Associates, a backer of Peninsula.
ROLLER-COASTER RIDE: More than five earthquakes ranging from magnitude 4.4 to 5.5 on the Richter scale shook eastern Taiwan in rapid succession yesterday afternoon Back-to-back weather fronts are forecast to hit Taiwan this week, resulting in rain across the nation in the coming days, the Central Weather Administration said yesterday, as it also warned residents in mountainous regions to be wary of landslides and rockfalls. As the first front approached, sporadic rainfall began in central and northern parts of Taiwan yesterday, the agency said, adding that rain is forecast to intensify in those regions today, while brief showers would also affect other parts of the nation. A second weather system is forecast to arrive on Thursday, bringing additional rain to the whole nation until Sunday, it
LANDSLIDES POSSIBLE: The agency advised the public to avoid visiting mountainous regions due to more expected aftershocks and rainfall from a series of weather fronts A series of earthquakes over the past few days were likely aftershocks of the April 3 earthquake in Hualien County, with further aftershocks to be expected for up to a year, the Central Weather Administration (CWA) said yesterday. Based on the nation’s experience after the quake on Sept. 21, 1999, more aftershocks are possible over the next six months to a year, the agency said. A total of 103 earthquakes of magnitude 4 on the local magnitude scale or higher hit Hualien County from 5:08pm on Monday to 10:27am yesterday, with 27 of them exceeding magnitude 5. They included two, of magnitude
CONDITIONAL: The PRC imposes secret requirements that the funding it provides cannot be spent in states with diplomatic relations with Taiwan, Emma Reilly said China has been bribing UN officials to obtain “special benefits” and to block funding from countries that have diplomatic ties with Taiwan, a former UN employee told the British House of Commons on Tuesday. At a House of Commons Foreign Affairs Committee hearing into “international relations within the multilateral system,” former Office of the UN High Commissioner for Human Rights (OHCHR) employee Emma Reilly said in a written statement that “Beijing paid bribes to the two successive Presidents of the [UN] General Assembly” during the two-year negotiation of the Sustainable Development Goals. Another way China exercises influence within the UN Secretariat is
Taiwan’s first drag queen to compete on the internationally acclaimed RuPaul’s Drag Race, Nymphia Wind (妮妃雅), was on Friday crowned the “Next Drag Superstar.” Dressed in a sparkling banana dress, Nymphia Wind swept onto the stage for the final, and stole the show. “Taiwan this is for you,” she said right after show host RuPaul announced her as the winner. “To those who feel like they don’t belong, just remember to live fearlessly and to live their truth,” she said on stage. One of the frontrunners for the past 15 episodes, the 28-year-old breezed through to the final after weeks of showcasing her unique